MACM
GNMK

March Altus Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

March Altus Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-223,818
Closed -$2.98M – 36
2013
Q4 		$2.98M Buy
+223,818
New +$2.72M 0.9% 28

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

March Altus Capital Management's GNMK Position: Q1 2014 in Review

March Altus Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2014, closing a stake of 223,818 shares — an estimated $2.98M sold.

March Altus Capital Management first reported a position in GNMK in Q4 2013 and held it in 1 quarter. The position peaked at $2.98M in Q4 2013. 78 funds tracked by Wall St. Rank hold GNMK as of Q1 2014.

  • March Altus Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q1 2014 after selling out during the quarter.
  • March Altus Capital Management sold 223,818 GenMark Diagnostics, Inc shares in Q1 2014, an estimated $2.98M.
  • March Altus Capital Management first reported a position in GenMark Diagnostics, Inc in Q4 2013 and held it in 1 quarter.
  • March Altus Capital Management's GenMark Diagnostics, Inc position peaked at $2.98M in Q4 2013.
  • 78 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2014.

Based on March Altus Capital Management's 13F filing for Q1 2014, filed 15 May 2014.